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INTRODUCTION 
An ultimate goal of any dosage regimen in the drug therapy of any disease is 
one which immediately attains the desired therapeutic concentration of drug in 
plasma (or at the site of action) and maintains it constant for the entire duration of 
treatment. This is possible through administration of a conventional dosage form in 
a particular dose and at a particular frequency. The frequency of administration or 
the dosing interval of any drug depends upon its half life or mean residence time 
(MRT) and its therapeutic index. Extended and controlled release represents 
separate drug delivery processes. Extended release (ER) constitutes any dosage form 
that provides medication over extended period of time. Controlled release, however, 
denotes that the system is able to provide some actual therapeutic control, whether 
this can be of temporal nature, spatial nature or both. In other words, the system 
attempts to control drug concentration in the target tissue. Thus there are sustained 
release systems that cannot be considered controlled drug delivery systems. The goal 
of ER1 dosage form is to maintain therapeutic blood or tissue levels of the drug for 
extended period which try to mimic zero-order drug release. Modified release oral 
dosage forms have brought new lease of life into drugs that have lost market 
potential due to requirement of frequent dosing, dose related toxic effects and gastro 
intestinal disturbances. 
Over past 30 year as the expanse and complication involved in marketing 
new drug entities have increased, with concomitant recognition of the therapeutic 
advantages of controlled drug delivery, greater attention has been focused on 
development of sustained or controlled release drug delivery systems. There are 
several reasons for the attractiveness of these dosage forms. It is generally 
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recognized that for many disease states, a substantial number of therapeutically 
effective compounds already exist. 
The effectiveness of these drugs, however, is often limited by side effects or 
the necessity to administer the compound in a clinical setting, the goal in designing 
sustained or controlled delivery system is to reduce the frequency of dosing or to 
increase effectiveness of the drug by localization at the site of action, reducing the 
dose required, or providing uniform drug delivery. Sustained release constitutes any 
dosage  form  that  provides  medication  over  and  extended  time.  Controlled  release,  
however, denotes that the system is able to provide some actual therapeutic control, 
whether this is of a temporal nature, spatial nature or both. 
This  correctly  suggests  that  there  are  sustain  release  system  that  cannot  be  
considered controlled release system. In general, the goal of a sustained release 
dosage form is to maintain therapeutic blood or tissue levels of drug for an extended 
period this is usually accomplished by attempting to obtain zero-order release from 
the dosage form; zero-order release constitutes drug release from the dosage form. 
Sustained release systems generally do not attain this type of release and provides 
drug is a slow first order fashion. In recent year sustained release dosage forms 
continue to draw attention in the search for improved patient compliance and 
decreased incidence of adverse drug reactions. Sustained release technology2 is 
relatively cow field and as a consequence, research in the field has been extremely 
fertile and has produced many discoveries. New and more sophisticated controlled 
release, sustained release delivery systems are constantly being developed and 
tested. 
 
3 
 
Department of Pharmceutics, Avpc  
 
Sustained release, sustained action, prolonged action controlled release, extended 
action, timed release, depot and repository dosage forms are terms used to identify 
drug delivery system that are designed to achieve or prolonged therapeutic effect by 
continuously releasing medication over an extended period of time after 
administration of a single dose. 
 
Fig.1.Plasma concentration-time profile 
 
Advantages of Extended release dosage forms 3 
Ø Reduction in dosing frequency. 
Ø Reduced fluctuations in circulating drug levels. 
Ø Increased patient compliance. 
Ø Extended release allows for sustained therapeutic blood levels of the drug. 
Ø Sustained blood levels provide for a prolonged and consistent clinical 
response in the patient. 
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Ø Economic benefit. 
Ø Minimize toxicity, decrease adverse reactions. 
Ø Drugs with very short elimination half-lives, an extended-release drug 
product maintains the efficacy over a longer duration. 
Disadvantages of extended release dosage forms 
Ø Dose dumping. 
Ø Reduced potential for dosage adjustment. 
Ø Poor systemic availability in general.                                                                                
Ø If the patient suffers from an adverse drug reaction or accidentally becomes 
intoxicated the removal of drug from the system is more difficult with an 
extended release drug product.                  
Ø Orally administered extended-release drug products may yield erratic or 
variable drug absorption as a result of various drug interactions with the 
contents of the GI tract and changes in the GI motility. 
Modified release drug product4-5 
The term modified release drug product is used to describe products that alter 
the timing and/or the rate of release of the drug substance. 
Types of Modified release drug products 
Ø Extended release dosage forms:A  dosage  form  that  allows  at  least  a  two  
fold reduction in dosage frequency as compared to that drug presented as an 
immediate release form. 
Ex: Controlled release, Sustained release. 
Sustained release:It includes any drug delivery system that achieves slow release of 
drugs over an extended period of time not particularly at a pre-determined rate. 
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Controlled release: It includes any drug delivery system from which the 
drug is delivered at a predetermined rate over a long period. 
Ø Delayed release dosage forms: A dosage form releases a discrete portion of 
drug at a time or times other than promptly after administration, although 
one portion may be released promptly after administration. 
Ex: Enteric coated dosage forms. 
Ø Targeted release dosage forms:A dosage forms that releases drug at /near 
the intended physiological site of action. Targeted release dosage forms may 
have extended release characteristics. 
Design of Extended release products 
Dissolution and diffusion controlled systems have classically been of 
primary importance in oral delivery of medication because of their relative ease of 
production and cost compared with other methods of sustained or controlled 
delivery. Most of these systems are solids, although a few liquids and suspension 
have been recently introduced. The classifications of such systems are as follows:  
Ø Diffusion controlled systems.  
Ø Dissolution controlled systems.  
Ø Dissolution and Diffusion controlled systems.  
Ø Osmotically controlled systems.  
Ø Ion exchange systems.  
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Diffusion controlled systems6 
Diffusion  systems  are  characterized  by  the  release  rate  being  dependent  on  its  
diffusion through an inert membrane barrier. Usually this barrier is an insoluble 
polymer.  
Ingeneral two types of sub classes of diffusion systems are recognized they are 
a. Réservoir devises.      
b. Matrix devises. 
a. Reservoir devices  
Reservoir devices are characterized by a core drug reservoir surrounded by a 
polymeric membrane. The nature of the membrane determines the rate of release of 
drug from the system. 
 The process of diffusion is generally described by Ficks equations, 
ܬ = ܦ ݀ܿ
݀ݔ
 
Where, J = Flux (amount/area –time)  
D = Diffusion co-efficient of drug in the membrane (area/time) 
dc/dx= rate of exchange in concentration C, with respect to a distance X in the 
membrane. 
b. Matrix devices  
 It contains of drug dispersed homogeneously throughout a polymer matrix. In 
this model, drug in the outside layer exposed to bath solution is dissolved first and 
then diffuses out of the matrix. The following equation describe the rate of release of 
drug dispersed in an inert matrix system have been derived by Higuchi. 
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ௗ௠
ௗ௛
=C0dh− େୱଶ . 
Where, dm = Change in the amount of drug released per unit area.  
dh= Change in the thickness of the zone of matrix that have been depleted of 
drug. 
 Co = Total amount of drug in unit volume of matrix. 
 Cs =Saturated concentration of drug within the matrix. 
Dissolution controlled systems7 
 Drug with a slow dissolution rate will demonstrate sustaining properties, since 
the release of the drug will be limited by rate of dissolution. This being the case, SR 
preparations of drugs could be made by decreasing their dissolution rate. This 
includes preparing appropriate salts or derivatives, coating the drug with a slowly 
dissolving material, or incorporating it into a tablet with a slowly dissolving carrier.  
    The dissolution process at steady state is described by Noyes-Whitney equation.        
ௗ௖
ௗ௧
=KܦA(Cs − C) = ୈ୅(େୱିେ)
௛
 
Where,dc/dt = Dissolution rate 
Ko    = Diffusion co-efficient 
           Cs     = Saturation solubility of the solid 
           C      = Concentration of solute in bulk solution. 
           h      = Thickness of diffusion layer. 
Dissolution and diffusion controlled release system 
 Strictly speaking, therapeutic systems will never be dependent on dissolution 
only or diffusion only. In practice, the dominant mechanism for release will over 
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shadow  other  processes  enough  to  allow  classification  as  either  dissolution  rate  
limited or diffusion controlled. 
Osmotically controlled systems 
 This device is fabricated as tablet that contains water soluble osmotically 
active drug, of that was blended with osmotically active diluents by coating the 
tablet with a cellulose triacetate barrier which functions as a semi permeable 
membrane. A laser is used to form a precision orifice in the barrier, through which 
the  drug  is  released  due  to  development  of  osmotic  pressure  difference  across  the  
membrane. 
Ion exchange Systems 
 These are salts of cationic or anionic exchange resins or insoluble complexes 
in which drug release results from exchange of bound drug ions that are normally 
present in GI fluids. 
 
Factors affecting Extended release dosage forms8 
Dose Size 
If an oral product has a dose size greater that 0.5gm it is a poor candidate for 
sustained release system, Since addition of sustaining dose and  possibly the 
sustaining mechanism will, in most cases generates a substantial volume product 
that unacceptably large. 
Aqueous Solubility  
Most of drugs are weak acids or bases, since the unchanged form of a drug 
preferentially permeates across lipid membranes drugs aqueous solubility will 
generally be decreased by conversion to an unchanged form for drugs with low 
water solubility will be difficult to incorporate into sustained release mechanism. 
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The lower limit on solubility for such product has been reported 0.1mg/ml. drugs 
with great water solubility are equally difficult to incorporate in to sustained release 
system. pH dependent solubility, particularly in the physiological pH range, would 
be another problem because of the variation in pH throughout the GI tract and hence 
variation in dissolution rate 
Partition coefficient  
Partition coefficient is generally defined as the fraction of drug in an oil 
phase to that of an adjacent aqueous phase. Accordingly compounds with relatively 
high partition coefficient are predominantly lipid soluble and consequently have 
very low aqueous solubility. Compounds with very low partition coefficients will 
have difficulty in penetrating membranes resulting poor bioavailability. 
pka 
It is the relationship between pka of compound and absorptive environment. 
Presenting drug in an unchanged form is adventitious for drug permeation but 
solubility decrease as the drug is in unchanged form 
Drug stability  
Orally administered drugs can be subject to both acid base hydrolysis and 
enzymatic degradation. Degradation will proceed at the reduced rate for drugs in the 
solid state, for drugs that are unstable in stomach, systems that prolong delivery ever 
the entire course of transit in GI tract are beneficial. Compounds that are unstable in 
the small intestine may demonstrate decreased bioavailability when administered 
form a sustaining dosage from. This is because more drug is delivered in small 
intestine and hence subject to degradation 
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Molecular size and diffusivity  
The ability of drug to diffuse through membranes its so called diffusivity & 
diffusion coefficient is function of molecular size (or molecular weight).Generally, 
values of diffusion coefficient for intermediate molecular weight drugs, through 
flexible polymer range from 10-8 to 10-9 cm2 / sec. with values on the order of 10-8 
being most common for drugs with molecular weight greater than 500, the diffusion 
coefficient   in  many  polymers  frequently  are  so  small  that  they  are  difficult  to  
quantify i.e. less than 16-12 cm2/sec.  Thus high molecular weight drugs and / or 
polymeric drugs should be expected to display very slow release kinetics in 
sustained release device using diffusion through polymer membrane. 
Biological half Life 
The usual goal of an oral sustained release product is to maintain therapeutic 
blood levels over an extended period. To action this, drug must enter in the 
circulation of approximately the same rate of which it is eliminated. The elimination 
rate is quantitatively described by half-life (t1/2). Therapeutic compounds with short 
half lives are excellent candidates for sustained release preparations. Since this can 
reduce dosing frequency. In general drugs with half-lives shorter than 3hrs are poor 
candidates of sustained release dosage forms of dose size will increase as well as 
compounds with long half lives, more than 8 hrs are also not used in sustained 
release forms because their effect is already sustained. 
Absorption 
The rate, extent and uniformity of absorption of a drug are important factors 
when considered its formulation into a sustained release system. As the rate limiting 
step in drug delivery from a sustained-release system is its release from a dosage 
form, rather than absorption. Rapid rate of absorption of drug, relative to its release 
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is essential if the system is to be successful. It we assume that transit time of drug  
must in the absorptive areas of the GI tract is about 8-12 hrs. The maximum half life 
for absorption should be approximately 3-4 hrs. Otherwise device will pass out of 
potential absorption regions before drug release is complete. 
Distribution 
The distribution of drugs into tissues can be important factor in the overall 
drug elimination kinetics. Since it not only lowers the concentration of circulating 
drug but it also can be rate limiting in its equilibrium with blood and extra vascular 
tissue, consequently apparent volume  of distribution assumes different values 
depending on time course of drug disposition. For design of sustained/ controlled 
release products, one must have information of disposition of drug. 
Metabolism 
Drugs that are significantly metabolized before absorption, either in lumen or 
the tissue of the intestine, can show decreased bioavailability from slower-releasing 
dosage forms. Most intestinal wall enzymes systems are saturable. As drug is 
released at a slower rate to these regions less total drug is presented to the 
enzymatic. Process device a specific period, allowing more complete conversion of 
the drug to its metabolite. 
Mechanism of drug release 
 
Fig.2. Drug delivery from a typical matrix drug delivery system. 
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Polymer and active agent have been mixed to form a homogeneous system, 
also referred to as a matrix system. Diffusion occurs when the drug passes from the 
polymer matrix into the external environment. As the release continues, its rate 
normally decreases with this type of system, since the active agent has a 
progressively longer distance to travel and therefore requires a longer diffusion time 
to release. 
Ideal candidates for Extended release drug delivery9 
Ø Molecular weight: <1000mg 
Ø Solubility: 0.1 mcg/ml 
Ø pka:  >0.1% to 1% at pH 1 to 7.8 
Ø Apparent partition coefficient: 0.5 to 2 
Ø Stability: stable in GI environment 
Ø Release: Release should not be influenced by pH and enzymes 
Ø Elimination Half Life; Preferably between 0.5 and 8hrs 
Ø Total clearance: Extensively metabolised by the liver provided the rate of 
metabolism is slow. 
Ø Intrinsic Absorption rate constant: Drug is absorbed rapidly 
Ø Therapeutic range: wide 
Unsuitable candidate for extended release dosage forms10 
Ø Shorter t1/2 
Ø Longer t1/2 
Ø Narrow Therapeutic index 
Ø Large dose 
Ø Not absorbed rapidly 
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LITERATURE REVIEW 
Shahrzad et al.,Explained that Hypromellose (hydroxypropyl methylcellulose, 
HPMC) matrices are widely used in the formulation of sustained release dosage 
forms. The integrity and performance of an HPMC matrix formulation depends on 
rapid hydration and gel formation upon ingestion. Due to the recent alert issued by 
the Food and Drug Administration regarding the potential negative influence of 
alcoholic beverages on extended release (ER) formulations, several researchers have 
evaluated the potential influence of hydro alcoholic media on drug release from ER 
dosage forms. It has been reported that HPMC matrix formulations do not show 
“dose dumping” in hydro alcoholic media. The purpose of this study was a 
fundamental investigation on the effect of hydro alcoholic solutions (0–40% v/v 
ethanol) on textural  and rheological properties of different viscosity grades of neat 
HPMC, as the functional ingredient within a hydrophilic matrix. In general, hydro 
alcoholic solutions had little effect on gel formation and mechanical properties of 
hydrated compacts, while the rheological behaviour of HPMC showed dependency 
on the ethanol content of such solutions. 
Amelia Avachat et al.,Employedan emulsion solvent evaporation method to prepare 
microspheres of ropinirole hydrochloride, a highly water soluble drug, by using 
ethyl cellulose and PEG with the help of 32 full factorial design. The microspheres 
were made by incorporating the drug in a polar organic solvent, which was 
emulsified using liquid paraffin as an external oil phase. Effects of various process 
parameters such as viscosity of the external phase, selection of the internal phase, 
surfactant selection and selection of stirring speed were studied. Microspheres were 
evaluated for product yield, encapsulation efficiency and particle size. Various 
14 
 
Department of Pharmceutics, Avpc  
 
drug/ethyl cellulose ratios and PEG concentrations were assayed. In vitro dissolution 
profiles showed that ethyl cellulose microspheres were able to control release of the 
drug for a period of 12 h. 
Juliane Weberet al., developed Two well designed, placebo- or active comparator- 
controlled trials examined the efficacy of ropinirole prolonged release in patients 
with advanced Parkinson’s disease sub optimally controlled by levodopa.  In the 
placebo-controlled trial, 24 weeks’ therapy with ropinirole prolonged release 6–24 
mg once daily reduced hours of ‘off’ time (primary endpoint) to a significantly 
greater extent than placebo. In active comparator-controlled trial, significantly more 
ropinirole prolonged-release recipients than ropinirole immediate-release recipients 
maintained at 20% reduction from baseline in ‘off’ time at plasma concentration 
week 24 (primary endpoint). This article focuses solely on the relative 
bioavailability of the prolonged- and immediate adjunct to levodopa in patients with 
advanced Parkinsons disease.   
R. Pahwa et al., Evaluated the efficacy of ropinirole 24-hour prolonged release 
(ropinirole 24-hour) as an adjunct to levodopa in patients with Parkinson disease 
(PD) and motor fluctuations. Methods: In a double-blind, placebo-controlled, 24-
week study, 393 subjects with PD were randomized to ropinirole 24-hour (n _ 202) 
or placebo (n _ 191). The primary outcome measure was reduction in hours of daily 
“off ” time. Results: At week 24, the mean dose of ropinirole 24-hour was 18.8 
mg/day with a mean reduction in daily levodopa of 278 mg. There was a mean 
reduction in daily “off ” time of 2.1 hours in the ropinirole 24-hour group and 0.3 
hours with placebo. Secondary outcome measures including change in hours and 
percent of daily “on” time and “on” time without troublesome dyskinesia, Unified 
PD Rating Scale motor and activities of daily living subscales, Beck Depression 
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Inventory-II, PDQ-39 subscales of mobility, activities of daily living, emotional 
well-being, stigma and communication, and PD Sleep Scale were significantly 
improved at week 24 with ropinirole 24-hour. The most common adverse events 
(AE) with ropinirole 24-hour were dyskinesia, nausea, dizziness, somnolence, 
hallucinations, and orthostatic hypotension and AEs led to study withdrawal in 5% 
of both the active and placebo groups. 
J. Goole et al., Studied the scintigraphic and pharmacokinetic studies were 
conducted on 10 healthy, fed volunteers. Two concepts of sustained-release floating 
minitablets – Levo-Form 1 (matrix) and 2 (coated) –were evaluated and compared to 
the marketed product Prolopa® HBS 125. All the floating forms were radio labelled 
with 111In in order to evaluate their gastric residence time using _-scintigraphy. It 
was shown that the three formulations offered almost the same mean gastric 
residence time, which was about 240 min. Prolopa® HBS 125 and Levo-Form 2 
presented intragastric disintegration, which can lead to a more pronounced “peak & 
valley” effect on the plasma concentration–time profile of levodopa. In contrast, the 
plasma concentration–time profile of levodopa following the administration of 
Levo-Form 1 was more evenly distributed. Moreover, Levo-Form 1 provided the 
lowest variations between men and women in terms of AUC and Cmax values. 
Finally, when the same amount of inhibitors of extra cerebral dopa decarboxylase – 
carbidopa and benserazide – had been administrated, the mean AUC, Cmax and 
Tmax values obtained for benserazide were lower than those obtained for carbidopa. 
Ranjith Kumar et al.,reviewed that oral drug delivery remains the most preferred 
option for administration for various drugs. Availability of wide variety of polymers 
and frequent dosing intervals helps the formulation scientist to develop 
sustained/controlled release products. Oral Sustained release (S.R) / Controlled 
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release (C.R) products provide an advantage over conventional dosage forms by 
optimizing bio-pharmaceutic, pharmacokinetic and pharmacodynamic properties of 
drugs in such a way that it reduces dosing frequency to an extent that once daily 
dose is sufficient for therapeutic management through uniform plasma concentration 
providing maximum utility of drug with reduction in local and systemic side effects 
and cure or control condition in shortest possible time by smallest quantity of drug 
to assure greater patient compliance. This review describes the various factors 
influencing the design and performance of sustained/controlled release products 
along with suitable illustrations. 
Peter Lewittet al.,described that Levodopa  serves  as  the  gold  standard  of  anti-
parkinsonian therapy and nearly every patient with Parkinson’s disease eventually 
receives this drug. To improve upon levodopa therapy, several forms of treatment 
have  been  devised  to  augment  its  actions,  and  new  delivery  systems  are  under  
development. This new research offers promise for improving outcomes with this 
highly effective therapy. 
Viness Pillay et al.,explained that Parkinson’s disease (PD) affects one in every 100 
persons above the age of 65 years, making it the second most common 
neurodegenerative disease after Alzheimer’s disease. PD is a disease of the central 
nervous system that leads to severe difficulties with body motions. The currently 
available therapies aim to improve the functional capacity of the patient for as long 
as possible; however they do not modify the progression of the neurodegenerative 
process. The need for newer and more effective agents is consequently receiving a 
great deal of attention and consequently being subjected to extensive research. This 
review concisely compiles the limitations of currently available therapies and the 
most recent research regarding neuroprotective agents, antioxidants, stem cell 
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research, vaccines and various surgical techniques available and being developed for 
the management of PD. 
Vincenzo Bonifati et al.,reviewed that Levodopa remains the most effective drug 
for  Parkinson’s  disease  (PD).  However,  its  benefits  are  limited  owing  to  extensive  
metabolism by catechol-O -methyltransferase (COMT), especially if levodopa is 
used in combination with peripheral dopa decarboxylase inhibitors. A new 
generation of potent, orally active, selective, and reversible COMT inhibitors has 
become available recently. Among these, tolcapone and entacapone have been best 
characterised. Preclinical and clinical studies have shown that COMT inhibitors 
markedly enhance levodopa availability and prolong its plasma half-life. In recent 
large clinical trials they proved to be able to ameliorate motor fluctuations, reduce 
disability, and decrease levodopa requirements in Parkinson disease patients. The 
tolerability profiles of entacapone and tolcapone are good. COMT inhibition 
promises to become an important means of extending the benefits of levodopa 
therapy in Parkinson disease. 
Adnan Azeem et al., designed an effective transdermal nano-emulsion drug 
delivery system can however resolve these issues effectively with greater therapeutic 
benefits and clinical significance. Therefore, the present work focuses precisely on 
pharmacokinetic, biochemical and mechanistic assessment of transdermal 
nanoemulsion gel in rats induced with Parkinson lesioned brain by 6-OHDA. DSC 
and FT-IR studies showed that NEG affects the normal lipid packing of stratum 
corneum  to  enhance  the  drug  permeation.  Study  of  pharmacokinetic  parameters  
(AUC, Cmax, and Tmax) revealed a greater and more extended release of ropinirole 
from  nanoemulsion  gel  compared  to  that  from  a  conventional  gel  (RPG)  and  oral  
marketed tablet (Ropitor®). The AUC0→∞ for RPCNG and RPTNG was found to 
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be 928.07 ± 206.5 and 1055.99 ± 251.7 ng h/mL, respectively in comparison to 
137.25 ± 31.3 and 467.15 ± 106.1 ng h/mL for RPG and oral tablet, respectively. 
The relative bioavailability of ropinirole has been enhanced more than two fold by 
RPTNG. Furthermore, antiparkinson activity was evaluated in terms of estimating 
the level of thiobarbituric acid reactive substances, glutathione antioxidant enzymes 
and catalase in lesioned brain of rats. Formulations were also found to be non-toxic 
and non-irritant by histological investigations. 
Lauren Seeberger et al.,explained that The bioavailability of drugs used to treat 
chronic diseases such as Parkinson’s disease may have important implications for 
their clinical utility. Drugs with low bioavailability may cause a wide variation in 
clinical response between patients and even in the same patient. In addition, 
numerous factors including gender, age, and gastric motility may affect a drug’s 
bioavailability. This is especially important in patients with Parkinson’s disease, 
who develop response fluctuations as the disease progresses. Strategies that may 
improve the bioavailability of levodopa, the most efficacious medication for 
Parkinson’s disease, include co administering levodopa with carbidopa, a 
decarboxylase inhibitor, or with a catechol- O-methyltransferase inhibitor or using 
an alternative route of administration. Other adjunctive therapies used to treat 
Parkinson’s disease have a wide range of bioavailability, which may also affect 
clinical outcomes. The bioavailability of adjunctive medications may be improved 
by the use of alternative formulations as well, such as orally disintegrating tablets or 
transdermal delivery. Considering bioavailability of a medication when prescribing 
drugs to treat Parkinson’s disease may improve patient response and minimize 
adverse effects. 
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Deepak Sahu et al.,developed sustained release matrix tablets of quetiapine 
fumarate using different polymers viz. Hydroxy propyl methyl cellulose (HPMC) 
and PVP K30. Varying ratios of drug and polymer like were selected for the study. 
After fixing the ratio of drug and polymer for control the release of drug up to 
desired time, the release rates were modulated by combination of two different rates 
controlling material and triple mixture of two different rate controlling material. 
After evaluation of physical properties of tablet, the in vitro release study was 
performed in 0.1 N HCl pH 1.2 for 2 hrs and in phosphate buffer pH 6.8 up to 12 
hrs.  The  effect  of  polymer  concentration  and  polymer  blend  concentration  were  
studied. Dissolution data was analysed by Higuchi expression. Among all the 
formulations, formulation QFSRT/08 which contains 60% HPMC K15M and 06% 
of PVP K30 release the drug which follow Higuchi kinetics via, swelling, diffusion 
and erosion and the release profile of formulation QFSRT/08 was comparable with 
the prepared batch products. Stability studies (40±2ºC/75±5%RH) for 6 months 
indicated that quetiapine fumarate was stable in the matrix tablets. The DSC and 
FTIR study revealed that there was no chemical interaction between drug and 
excipients. 
Wakode Rajeshri et al.,developed  Sustained  release  tablets  of  pramipexole  to  be  
taken once daily were formulated and characterized. Matrix system based on 
combination of different polymers like hydroxy propyl methylcellulose (HPMC), 
Eudragit RL 100 and ethyl cellulose in varying concentrations were studied to get 
the desired sustained release profile over a period of 24 h. The granules were 
evaluated for angle of repose, bulk density, compressibility index, and drug content. 
The granules showed satisfactory flow properties, compressibility and drug content. 
The release pattern of pramipexole was fitted to different models based on 
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coefficient of correlation. Formulation (F10) containing HPMC (16% w/w) and 
Ethyl cellulose (5.4 % w/w) gave the desired release for once a day administration. 
The drug release was found to be diffusion controlled coupled with erosion having 
high correlation for Higuchi release pattern. The release pattern was close to the 
theoretical release profile. 
Raghavendra Rao et al., has developed sustained release matrix tablets of water 
soluble Tramadol hydrochloride using different polymers viz. hydroxy propyl 
methyl cellulose (HPMC) and natural gums like Karaya gum (KG) and Carrageenan 
(CG). Varying ratios of drug and polymer like 1:1 and 1:2 were selected for the 
study. After fixing the ratio of drug and polymer for control the release of drug up to 
desired time, the release rates were modulated by combination of two different rates 
controlling material and triple mixture of three different rate controlling material. 
After  evaluation  of  physical  properties  of  tablet,  the  in vitro release study was 
performed in 0.1 N HCl pH 1.2 for 2 hrs and in phosphate buffer pH 6.8 up to 12 
hrs.  The  effect  of  polymer  concentration  and  polymer  blend  concentration  were  
studied. Different ratios like 80:20, 60:40, 50:50, 40:60 and 20:80 were taken. 
Dissolution data was analyzed by Korsmeyer-Peppas power law expression and 
modified power law expression. It was observed that matrix tablets contained 
polymer blend of HPMC/CG were successfully sustained the release of drug up to 
12 hrs. Among all the formulations, formulation F16 which contains 20% HPMC 
K15M and 80% of CG release the drug which follow Zero order kinetics via, 
swelling, diffusion and erosion and the release profile of formulation F16 was 
comparable with the marketed product. Stability studies (40±2ºC/75±5%RH) for 3 
months indicated that Tramadol hydrochloride was stable in the matrix tablets. The 
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DSC and FTIR study revealed that there was no chemical interaction between drug 
and excipients. 
Yucheng Sheng et al.,Evaluated an understanding of dose proportionality is 
essential in drug development, and the results are of great clinical importance for 
predicting the effects of dose adjustments. However, little consensus exists with 
regard to study design and analysis. The aim of this paper was to produce a detailed 
profile of the information on dose proportionality studies in the last 10 years and to 
provide a foundation for reflection and debate on future priorities. A total of 147 
publications comprising 156 studies were analyzed. The typical dose proportionality 
study enrolled 20 to 30 subjects and randomly allocated them into 3 to 4 dose levels 
to investigate pharmacokinetic behaviours within a dose ratio range of 2-6. The most 
common  design  was  the  crossover  experiment  (52.6%),  and  evaluating  dose-
adjusted pharmacokinetic parameters followed by hypothesis testing (43%) was the 
most frequent statistical approach. However, the alternative crossover design and 
equivalence criterion based on the power model represented only 4% and 8% of 
studies, respectively. The power model as a recommendable empirical relationship 
to assess dose proportionality was applied in 25 (16%) studies. This research 
suggests that the alternative crossover design and power model statistical method 
should be attracting more attention in order to obtain more information in studies 
with limited subjects. 
Eytan Klausner et al., reviewed levodopa has to be administered continuously to 
the upper parts of the intestine in order to maintain sustained therapeutic levels. This 
may be achieved by a controlled release (CR) gastro retentive dosage form (GRDF). 
The aim of this work was to develop a novel GRDF, based on unfolding polymeric 
membranes, that combines extended dimensions with high rigidity, and to examine 
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the pharmacokinetics of levodopa compounded in the GRDF. The 21 successful CR-
GRDF maintained therapeutic levodopa concentrations (.500 ng ml ) over 9 h. In 
comparison to non-gastro retentive CR-particles and oral solution, mean absorption 
time was significantly extended. These outcomes demonstrate that the CR-GRDF 
may be used to improve levodopa therapy and can be applied to extend the 
absorption of other narrow absorption window drugs that require continuous input. 
  
  
 
 
 
 
 
 
 
 
 
 
Drug Profile 
23 
 
Department of Pharmceutics, Avpc  
 
 
DRUG PROFILE27-30 
ROPINIROLE 
IUPAC Name:  4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one  
Chemical structure 
 
Molecular formula: C16H24N2O 
Molecular weight: 296.84 gm/mol 
Therapeuic action 
Anti-parkinsonism 
Mechanism of action28 
Ropinirole is a non-ergoline dopamine agonist with high relative in vitro 
specificity and full intrinsic activity at the D
2 
and D
3 
dopamine receptor subtypes, 
binding with higher affinity to D
3 
than to D
2 
or D
4 
receptor subtypes.It acts on post 
synaptic neurons, acting selectively on Dopamine D2/D3 receptors and helps to 
improves motor function. It belongs to Dopaminergic agonist 
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Pharmacokinetcs29 
Route: oral 
Bioavailability 
In clinical studies with immediate-release ropinirole, over 88% of a 
radiolabeled dose was recovered in urine, and the absolute bioavailability was 45% 
to 55%, indicating approximately 50% first-pass effect. Ropinirole displayed linear 
kinetics up to doses of 24 mg/day (8 mg immediate-release, 3 times a day). Relative 
bioavailability of REQUIP XL Extended-Release Tablets compared with immediate-
release tablets was approximately 100%. 
Distribution 
Ropinirole is widely distributed throughout the body, with an apparent 
volume of distribution of 7.5 L/kg 
Metabolism 
Ropinirole is extensively metabolized by the liver. The major metabolic 
pathways are N-despropylation and hydroxylation to form the inactive N-despropyl 
metabolite and hydroxyl metabolites. 
Elimination 
 Less than 10% of the administered dose is excreted as unchanged drug in urine. 
Adverse reactions29 
The following adverse reactions are observed in  ropinirole include 
Ø Falling asleep during activities of daily living  
Ø Syncope  
Ø Symptomatic hypotension, hypotension, postural/orthostatic hypotension  
Ø Elevation of blood pressure and changes in heart rate  
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Drug interactions 
Ciprofloxacin 
Co administration of ciprofloxacin, an inhibitor of CYP1A2, with ropinirole 
increased ropinirole AUC by 84% on average and C
max 
by 60%  
L-dopa 
Oral administration of ropinirole increased mean steady-state C
max 
of L-dopa 
by 20%, but its AUC was unaffected 
Estrogens 
Population pharmacokinetic analysis revealed that higher doses of estrogens 
(usually  associated  with  hormone  replacement  therapy  [HRT])  reduced  the  oral  
clearance of ropinirole by approximately 35%.  
Warnings and precautions30 
Ø Syncope, sometimes associated with bradycardia,  
Ø Symptomatic hypotension (including postural/orthostatic hypotension)  
Ø Elevation of blood pressure and changes in heart rate                                                  
Ø Hallucination may occur                                                                                                           
Ø Dyskinesia may be caused or exacerbated. Decreasing the L-dopa dose may 
lessen or eliminate this side effect 
Dosage forms and strengths                                                                                     
Tablets: 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg  
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POLYMER PROFILE 
HYDROXY PROPYL METHYL CELLULOSE31-33 
Nonproprietary Names 
BP: Hypromellose, JP: Hydroxypropylmethylcellulose 
PhEur: Hypromellosum, USP: Hypromellose 
Synonyms 
Hydroxyl propyl methylcellulose, HPMC; Methocel, methyl cellulose, propylene 
glycol ether; methyl hydroxypropylcellulose; Metolose; Tylopur. 
Empirical Formula and Molecular Weight 
  The PhEur 2005 describes hypromellose as a partly O-methylated and O-(2 
hydroxypropylated) cellulose. It is available in several grades that vary in viscosity and extent 
of substitution. Molecular weight is approximately 10 000–1 500 000. 
Structural formula 
 
                          Where R is H, CH3, or CH3CH(OH)CH2 
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Description 
Hypromellose is an odourless and tasteless, white or creamy white fibrous or 
granular powder. 
Typical Properties                                                                                                              
Density (bulk): 0.341 g/cm3Melting point: Browns at 190–2000CMoisture content: 
Hypromellose absorbs moisture from the atmosphere; 
Functional Category 
Coating agent; film-former; rate-controlling polymer for sustained release; 
stabilizing agent; suspending agent; tablet binder; viscosity-increasing agent. 
Applications in Pharmaceutical Formulation or Technology 33 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in 
film-coating, and as a matrix for use in extended-release tablet formulations. 
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or 
dry-granulation processes. High-viscosity grades may be used to retard the release of 
drugs from a matrix at levels of 10–80% w/w in tablets and capsules. 
Depending upon the viscosity grade, concentrations of 2–20% w/w are used 
for film-forming solutions to film-coat tablets. Hypromellose is also used as a 
suspending and thickening agent in topical formulations. Hypromellose at 
concentrations between 0.45–1.0% w/w may be added as a thickening agent to 
vehicles for eye drops and artificial tear solutions. 
Hypromellose is also used as an emulsifier, suspending agent, and stabilizing 
agent in topical gels and ointments. As a protective colloid, it can prevent droplets 
and particles from coalescing or agglomerating, thus inhibiting the formation of 
sediments. In addition, hypromellose is used in the manufacture of capsules, as an 
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adhesive in plastic bandages, and as a wetting agent for hard contact lenses. It is also 
widely used in cosmetics and food products 
SODIUM CARBOXY METHYL CELLULOSE 
Nonproprietary Names 
BP: Carmellose sodium,JP: Carmellose sodium,                                                                                                              
PhEur: Carmellosum natricum, USP: Carboxymethylcellulose sodium  
Synonyms 
Akucell; Aquasorb; Blanose; cellulose gum; CMC sodium; E466; Finnfix; Nymcel; 
SCMC; sodium carboxy methyl cellulose; sodium cellulose glycolate; sodium CMC; 
Tylose CB. 
Empirical Formula and Molecular Weight 
The USP describes carboxymethylcellulose sodium as the sodium salt of 
polycarboxymethyl ether of cellulose. Typical molecular weight is 90 000–700 000. 
Structural Formula  
 
Description 
Carboxymethylcellulose sodium occurs as a white to almost white, 
odourless, granular powder. 
Typical Properties                                                                                                                         
Density (bulk): 0.52 g/cm3Density (tapped): 0.78 g/cm3Dissociation constant: pKa 
= 4.30Melting point: chars atapproximately 2520C.Moisture content: typically 
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contains less than 10% waterSolubility: practically insoluble in acetone, ethanol 
(95%), ether, and toluene. Easily dispersed in water at all temperatures, forming 
clear, colloidal solutions. 
Functional Category 
Coating agent; stabilizing agent; suspending agent; tablet and capsule 
disintegrant; tablet binder; viscosity-increasing agent; water-absorbing agent. 
Applications in Pharmaceutical Formulation or Technology 35 
Carboxymethylcellulose sodium is widely used in oral and topical 
pharmaceutical formulations, primarily for its viscosity increasing properties. 
Carboxymethylcellulose sodium may also be used as a tablet binder and 
disintegrant, and to stabilize emulsions. Higher concentrations, usually 3–6%, of the 
medium  viscosity  grade  are  used  to  produce  gels  that  can  be  used  as  the  base  for  
applications and pastes. Uses of carboxymethylcellulose sodium. 
Table No: 1 Use and Concentration of Carboxy methyl cellulose sodium 
Use Concentration (%) 
Emulsifying agent 0.25–1.0 
Gel-forming agent 3.0–6.0 
Injections 0.05–0.75 
Oral solutions 0.1–1.0 
Tablet binder 1.0–6.0 
 
POVIDONE36 
Nonproprietary Names 
BP: Povidone, JP: Povidone, PhEur: Povidonum, USP: Povidone,  
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Synonyms 
E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl) ethylene]; polyvidone; 
poly vinyl pyrrolidone; PVP; 1-vinyl-2-pyrrolidinone polymer 
Chemical Name                                                                                                                              
1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical Formula and Molecular Weight 
(C6H9NO)n   and 2500–3 000000                                                                                     
 
Table No: 2 Viscosity grades of Povidone 
K-value Approximate molecular weight 
12 2500 
15 8000 
17 10 000 
25 30 000 
30 50000 
60 400000 
90 1000 000 
 
 
 
Structural Formula 
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Description 
Povidone occurs as a fine, white to creamy-white coloured, odourless or 
almost odourless, hygroscopic powder. 
Typical Properties                                                                                                     
Density (bulk): 0.29–0.39 g/cm3Density (tapped): 0.39–0.54 g/cm3                                                                                                
Melting point: softens at 1500C.                                                                                                
Functional Category 
 Disintegrant; dissolution aid; suspending agent; tablet binder. 
Applications in Pharmaceutical Formulation or Technology 
Although povidone is used in a variety of pharmaceutical formulations, it is 
primarily used in solid-dosage forms. In tableting, povidone solutions are used as 
binders in wet granulation processes. 
 
 
 
 
 
Table No: 3 Use and Concentration of Povidone 
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Use of povidone Use Concentration (%) 
Carrier for drugs 10–25 
Dispersing agent Up to 5 
Eye drops 2–10 
Suspending agent Up to 5 
Tablet binder, tablet diluent, or coating 
agent 
0.5-5 
 
ETHYL CELLULOSE37 
Nonproprietary Names 
BP: Ethyl cellulose 
PhEur: Ethyl cellulosum 
USPNF: Ethyl cellulose 
Synonyms 
Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
Chemical Name  
Cellulose ethyl ether  
Empirical FormulaC12H23O6(C12H22O5)nC12H23O5 where n can vary to provide a 
wide variety of molecular weights. 
 
 
 
Structural Formula  
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Description 
Ethyl cellulose is a tasteless, free-flowing, and white to light tancolored powder. 
 
Typical Properties 
Density (bulk): 0.4 g/cm3                                                                                                             
Solubility: ethyl cellulose is practically insoluble in glycerine,propylene glycol, and 
water.Specific gravity: 1.12–1.15 g/cm3                                                                                                         
Glass transition temperature: 129–1330C 
Functional Category 
Coating agent; flavouring fixative; tablet binder; tablet filler; viscosity-
increasing agent. 
Applications in Pharmaceutical Formulation or Technology 
Ethyl cellulose is widely used in oral and topical pharmaceutical 
formulations. The main use of ethyl cellulose in oral formulations is as a 
hydrophobic coating agent for tablets and granules. Ethyl cellulose coatings are used 
to  modify  the  release  of  a  drug,  to  mask  an  unpleasant  taste,  or  to  improve  the  
stability of a formulation; 
Uses of ethyl cellulose 
 
Table No: 4 Use and Concentration of Ethyl cellulose 
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Use Concentration (%) 
Microencapsulation 10.0–20.0 
Sustained-release tablet coating 3.0–20.0 
Tablet coating 1.0–3.0 
Tablet granulation 1.0–3.0 
 
OPADRY WHITE 
Opadry white aqueous moisture barrier film coating system is available in 
pigmented or white form only. The polymer was specially developed for the coating 
of oral solid dosage forms that need to be protected from environmental moisture. It 
is applied in an aqueous process, to form a pH independent, water soluble film 
coating. On a tablet this coating will function as a barrier to mask an unpleasant taste 
with no effect on the release profile of the drug. 
Composition: HPMC, Talc, Titanium dioxide, polyvinyl alcohol 
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SUITABILITY OF DRUG 
Ø Ropinirole, a nonergoline dopamine agonist, has been used to treat the motor 
symptoms of Parkinson’s disease due to stimulation of postsynaptic 
dopamine D2 type receptors. 
Ø Ropinirole is recommended to reduce motor fluctuation in patients with 
advanced Parkinson’s disease and usually associated with mild side effects 
like nausea, sleepiness, fatigue, etc when compared to other dopaminergic 
agonists, ergot derivatives.  
Ø Ropinirole is USFDA approved product, 1st line of drug for the treatment of 
Parkinson’s disease.  
Ø Owing to its moderate elimination half-life, the immediate-release 
formulation is administered three-times daily. The prolonged- release 
formulation is associated with fewer fluctuations in plasma concentration, 
allowing for symptomatic treatment for the entire day with once-daily 
dosing.Absolute Bioavailability is 50% and Relative Bioavailability is 100% 
when compared to immediate release tablet forms. 
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AIM AND OBJECTIVE OF THE WORK 
           The aimof the present study was to formulate and evaluate extended release 
tablets of ropinirole 
 The main objectives of the present work are 
Ø To reduce Dosing frequency of drug by sustaining its release. 
Ø To Study Drug and Polymer interactions. 
Ø To develop Stable, pharmaceutically equivalent formulation. 
Ø Compare the developed formulation with that of reference formulation. 
Ø To develop cost effective medicine when compared to marketed products. 
Ø Short term stability study of the optimized formulation according to ICH 
Guidelines. 
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PLAN OF WORK 
    The present work was carried out to prepare Ropinirole Extended Release 
tablets, the stages involved in the plan of work are as follows. 
v Literature survey based on. 
o Drug 
o Polymers 
v Characterization of innovator product 
v Preformulation studies 
o Preformulation studies of API 
o Compatibility studies with Excipient by HPLC 
o Finalized Selection of Excipient 
v Analytical method development 
v Product development 
o Selection of process 
o Formulation development 
o Process optimization 
o Finalized process 
o Finalized formula 
v Formulation Evaluation  
Evaluation of Granules 
o Bulk and Tapped density 
o Angle of repose 
o Compressibility index 
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o Hausner ratio 
Physico chemical Evaluation 
o Thickness 
o Hardness 
o Friability 
o Weight variation 
o Drug content 
v Comparision of Test formulation with Reference product 
v Stability Studies 
o As per ICH guidelines upto 3 months in HDPE Bottles 
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MATERIALS USED 
Table No: 5 Materials used in formulation 
S.no Name Manufacturers Name 
1 Ropinirole HCl Dr Reddy lab: unit(2) 
2 HPMC K100M FMC Biopolymer 
3 HPMC K15M Colorcon 
4 PVP K90 Colorcon 
5 Sodium Caboxy methyl cellulose  Sd fine Chemicals, Mumbai 
6 Anhydrous Lactose Qualigens Fine chemicals 
7 Colloidal Sio2 Sd fine Chemicals, Mumbai 
8 Mg.stearate Qualigens Fine chemicals 
9 Ethyl cellulose Sd fine Chemicals, Mumbai 
10 Opadry white Merck private limited 
11 Tri ethyl citrate Merck private limited 
12 Isopropyl alcohol Dr Reddy lab 
13 Dichloromethane Dr Reddy lab 
14 Opadry pink Merck private limited 
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EQUIPMENTS USED 
Table No: 6 Instruments used in the formulation 
S.no Equipment Manufacturer Name 
1 Digital Balance Sagtorious 
2 Electronic Balance Metler 
3 Tapped density Electrolaab 
4 Hardness and Thickness Varian 
5 Friabilator Roche Friabilator 
6 In vitro dissolution apparatus Electro lab 
7 HPLC Waters-Empower 
8 Granulation Roller compacter 
9 Blender Double cone blender 
10 Rotary Compression Machine  Cadmach,10 Station Press  
11 Coating Gansons 
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EXPERIMENTAL WORK 
Generic drug 
        Generic drug is defined as "a drug product that is comparable to 
brand/reference listed drug product in dosage form, strength, route of administration, 
quality an performance characteristics, and intended use. 
Innovator 
GlaxoSmithKline, USA 
Strength 
2 mg 
Innovator  
         Tri layered formulation, Central active medicament and two placebo outer 
layers    act as barrier layers which control surface area available for drug release. 
 
Figure.3. Innovator Tri layered Formulation 
        A number of barrier compositions were formulated and tested to reach the most 
suitable  control  of  the  dissolution  process.  In  particular  a  barrier  made  up  of  high  
viscosity hydroxyl propyl methylcellulose (HPMC), which is characterized by very 
slow hydration38 and gelling rates, provides an excellent protection of the coated 
surfaces of the active core for extended times. This type of barrier, being quite 
impermeable to drug diffusion for long periods of time, is particularly useful to 
control the release of soluble drugs for once a day administration.  
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Figure.4. Geomatrix three-layer system 
Characterization of Innovator product 
Table No: 7 Physical characterization of Innovator 
S.no Description Innovator (REQUIP XL) 
1 Lable claim 2.28 mg of ropinirole hydrochloride 
equivalent to 2 mg of  ropinirole 
2 Shape Biconvex, capsule-shaped 
3 Hardness(kp) 12±1 kp 
4 Thickness(mm) 6.6±0.2 mm 
5 Weight (mg) 490 mg 
6 Colour Pink 
7 Embossing “GS & 3V2” 
Inactive Ingredients: Carboxy methyl cellulose sodium, Colloidal silicon dioxide, 
glycerol biphenate, Hydrogenated Castor oil, Anhydrous Lactose, Magnesium 
stearate, Polyethylene glycol, Titanium dioxide, Mannitol, Povidone, Ferric 
oxides(Black,red,yellow) 
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Preformulation studies39 
         Before formulation of drug substances into a dosage form, it is essential that 
drug polymer should be chemically and physically characterized. Preformulation 
studies gives the information needed to define the nature of the drug substance and 
provide a framework for the drug combination with pharmaceutical excipients in the 
manufacture of a dosage form. 
Particle size 
         Particle size distribution by Malvern instrument, it is based on laser diffraction 
technique. Principle involved is particle size is inversely proportional to diffraction 
that smaller particles diffract more and larger particles will diffract less from this 
percentage of particles within the microns is calculated. 
Solubility 
         Ropinirole HCl is soluble in water and the saturation solubility was conducted 
in various media such as  
Table No: 8 Solubility in different Media 
S.no Solubility medium Solubility(mg/ml) 
1 0.1N HCl 107.0 
2 0.01N HCl 124.8 
3 pH 4.5 acetate buffer 140.9 
4 pH6.8 phosphate buffer 121.4 
5 pH 7.2 phosphate buffer 122.7 
6 Purified water 138.5 
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Melting point 
        A glass capillary tube is normally used to contain the sample for a melting 
point determination. Therefore the tube must have one open end into which the 
sample can be loaded, and one sealed end so that the capillary will retain the solid 
sample. Use a spatula to gather the powder into a small pile. The height of solid in 
the capillary should be no more than 1-2 mm. The melting point of the sample can 
be determined till the sample gets charred.  
Table No: 9 Preformulation parameters for Active pharmaceutical 
ingredient 
Solubility Soluble in water and it is 133 mg/ml 
Bulk density 0.27 ± 0.2 gm/ml 
Tapped density 0.46±0.4 gm/ml 
Compressibility index (%) 41.3%±0.5 
Hausner Ratio 1.7±0.4 
Melting point 248°C 
Table No: 10 Flow properties For API+ Excipient mixed 
1 Bulk density(g/ml) 
 
0.4692±0.04 
2 Tapped density(g/ml) 0.55±0.03 
 
3 Carr’s index 
 
14.6±0.52 
 
4 Hausner ratio 
 
1.17±0.03 
 
5 Angle of repose(Ө) 
 
28.24±1.86 
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Drug Excipient Compatibility 
        Based on innovator composition and availability data following listed 
Excipients were selected. Drug and Excipients were passed through 40 mesh screen 
and mixed uniformly and loaded in glass vials as per the ratios given as follows40 
Table No: 11 Ratios of Drug-Excipient 
S.no 
 
Excipient Ratio (Drug –Excipient) 
 
1 HPMC K100M 1:20 
2 HPMC K15M 1:15 
3 PVP K90 1:10 
4 Ethyl cellulose 1:10 
5 Magnesium stearate 1:5 
6 Colloidal silicon dioxide 1:5 
7 Stearic acid 1:5 
8 Glyceryl stearate 1:5 
9 PEG 6000 1:5 
10 Citric acid 1:10 
11 Triethylcitrate 1:2 
12 Anhydrous Lactose 1:10 
13 Opadry white 1:5 
14 Opadry pink 1:5 
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Table No: 12 Impurities in Initial and Final week 
Ingredi
ent 
Initial week  Impurities Fourth week Impurities 
Des 
proy
l 
N-
Met
hyl 
OH 
3-
OX
O 
N-
oxid
e 
Tota
l 
Despro
pyl 
N-
Met
hyl 
OH 
3-
OXO 
N-
oxid
e 
Total 
HPMC 
K100M 
0.12
68 
ND 0.19
32 
ND 0.32
00 
0.1143 0.01
08 
0.154
9 
ND 0.280
0 
PVP 
K90 
0.09
56 
ND 0.13
98 
0.05
60 
0.29
14 
0.0943 0.01
25 
0.079
1 
0.41
06 
0.596
5 
Ethyl 
cellulos
e 
0.14
03 
ND 0.25
20 
ND 0.39
23 
0.1092 ND 0.467
4 
0.02
61 
0.602
7 
Mg. 
Stearate 
0.11
19 
ND 0.17
40 
0.00
66 
0.29
25 
0.1133 ND 0.191
8 
ND 0.305
1 
Colloid
al sio2 
0.12
53 
ND 0.46
79 
0.00
86 
0.60
18 
0.1340 ND 1.369 ND 1.503
0 
Stearic 
Acid 
0.10
05 
ND 0.17
52 
ND 0.27
57 
0.1478 ND 0.249
4 
ND 0.397
2 
Glycery
l 
stearate 
0.12
46 
ND 0.23
09 
ND 0.35
55 
0.1142 ND 0.406
3 
0.01
04 
0.530
9 
PEG 0.11 ND 0.18 ND 0.29 0.2006 ND 0.148 0.08 0.433
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Finalized selection of Excipients 
        For the development of an extended release dosage form a polymer with slow 
gelling property like HPMCK 100M is required. Since ropinirole is absorbed 
through out GIT, the matrix must also possess the capability of controlling the drug 
release over 24hrs for which fast gelling polymers like HPMCK 15M was used for 
obtaining precise control over the initial phases of release of the drug. Carboxy 
methyl cellulose sodium provides a synergistic effect. Povidone, a release modifier 
was used to obtain completeness of release from the matrix. Colloidal silicon 
dioxide acts as glidant to improve the flow of blend. Magnesium stearate was used 
as lubricant 
 
6000 30 06 36 7 46 9 
Tri 
ethyl 
citrate 
0.08
22 
ND 0.14
15 
ND 0.22
37 
0.1403 ND 0.209
8 
ND 0.350
1 
Citric 
acid 
0.07
49 
ND 0.34
30 
ND 0.41
79 
0.0681 ND 14.02
03 
0.04
32 
14.13
16 
An. 
Lactose 
0.13
67 
ND 0.20
97 
ND 0.34
64 
0.1263 ND 0.180
6 
ND 0.306
9 
Opadry 
white 
0.12
96 
ND 0.18
95 
ND 0.31
91 
0.1250 ND 0.184
0 
0.02
58 
0.334
8 
Opadry 
pink 
0.13
15 
ND 0.20
23 
ND 0.33
38 
0.1611 ND 0.331
1 
ND 0.492
2 
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Table No: 13 Finalized Selection of Excipients 
S.no 
 
Ingredient 
 
Pharmaceutical  function 
 
1 HPMC K100M Rate controlling polymer 
2 HPMC K15M Rate controlling polymer 
 
3 Sodium carboxy methyl     
cellulose  
 
Rate controlling polymer 
 
4 PVPK 90 
 
Rate controlling polymer 
 
5 Anhydrous Lactose 
 
Diluent 
 
6 Colloidal Sio2 
 
Anti-adherent 
 
7 Mg.stearate 
 
Lubricant 
 
Functional coating 
 
8 Ethyl cellulose 
 
Coating agent 
 
9 Opadry white Channel forming agent 
 
10 Triethyl citrate 
 
Plasticizer 
11 Dichloromethane 
 
Coating vehicle 
 
12 Isopropyl alcohol Coating vehicle 
Film coating 
13 Opadry pink Coating agent 
 
14 Purified water 
 
Coating vehicle 
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ANALYTICAL METHOD DEVELOPMENT 
Innovator medium (pH 4 Citrate buffer) 
  Mix 5ml of 0.2M Citric acid and 85ml of 0.2M disodium citrate and dilute 
to 100ml with purified water. if required adjust pH to 4 with dil.NaOH 
0.2M Citric acid 
 42.03gm of citric acid Monohydrate dissolved in 1000ml purified water 
0.2M Disodium citrate dihydrate 
 58.82gm of disodium citrate dihydrate in 1000ml purified water 
Table No: 14 Requirements in Dissolution 
Medium pH 4 Citrate buffer 
Quantity 500ml 
Apparatus USP Type 2(paddle) 
RPM 100 rpm 
Temperature 37±0.50c 
 
DISSOLUTION BY HPLC41 
Mobile phase: Buffer: Acetonitrile (70:30) 
Standard stock solution 
 Weigh accurately about 73 mg of Ropinirole HCl Reference/working 
standard to 200ml volumetric flask add 130 ml milliQ water sonicate and made up to 
the mark. 
Standard Preparation 
 Pipette 5ml of standard stock into 100ml volumetric flask and dilute through 
milliQ water, filter through 0.2µm whattman filter paper42 
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Equipment                            - Waters type with UV detector 
Column Temperature              -   300c 
 Flow Rate                              - 1.2ml/min 
 Injection volume                    - 60µL 
System suitability 
Calculation: Tailing not more than 243 
Inject 60 µL Portion of dissolution medium of test preparation 
Qty of Ropinirole dissolved in nth time interval 
ܣݐ
ܣݏ
× ܹݏ200 × 5100 × 500ܰ × 255 × ܲ100 × 100ܮ  
             At -Peak Area of test preparation in nth time 
             As –Peak Area of standard preparation 
             ws- Weight of Ropinirole HCl working standard taken in mg 
              P -Potency of Ropinirole working standard 
              N –No. of tablets taken 
              L -Labelled amount of Ropinirole (2mg)  
PRODUCT  DEVELOPMENT 
        Product development involves two stages; it involves Formulation and Process 
development.  
Selection of process 44 
Direct compression 
        Milling the drug and excipients like HPMC, CMC sodium, anhydrous lactose, 
povidone through 40 mesh screen and mixing of drugs and excipients then go for 
direct compression of tablet 
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Wet granulation 
        Millingand mixing of drugs and excipients like HPMC,CMC sodium, 
Anhydrous lactose, prepare the povidone binder solution and is introduced in RMG 
granulator which contained blending material and granules is formed by impeller 
and chopper amperage adjustment and wet granules is formed. The formed granules 
are dried in fluidised bed dryer. The dried granule is placed in blender and colloidal 
silicon dioxide and magnesium stearate is added, then compress the tablet. 
Dry granulation 
        Sift the material through 30 mesh and mixing of drug and excipients like 
HPMC, Sodium CMC, Anhydrous lactose, pass through roller compactor results in 
formation of ribbon shaped flakes then pass the flakes in vibratory granulator 
formation of granules. These granules passed through blender where colloidal 
silicon dioxide and magnesium stearate is added and compress the tablet. 
From above issues we consider that dry granulation is preferred method and all the 
optimization of formula is done with dry granulation process 
.  
Figure.5. Roller compactor 
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Formulation development 
 Formulation development involves following stages of optimization of 
excipients. 
Optimization of rate controlling polymers 
        During this stage, optimization of polymers using Hydrophilic45 and 
Hydrophobic polymers was done. The percentage of drug release using Hydrophilic 
polymers is more compared to hydrophobic polymers and therefore finalised use of 
Hydrophilic  polymers.  In  all  these  dissolution  performed  with  H.P.L.C,  and  the  
average of 4 tablets is mentioned here. 
Procedure 
Ø Rinse API with Anhydrous Lactose part 1 and pass through 30 mesh screen, 
Sift together HPMC K100M, HPMC K15M46 Castor oil, Stearic acid in four 
different formulation and pass through 30 mesh screens.  
Ø Sift the contents of Anhydrous Lactose part 2 with colloidal silicon dioxide 
and magnesium stearate of part 1 and pass through 30 mesh screen and to 
this PVP K90 is added.  
Ø Blend  the  entire  contents  for  10  minutes  and  subject  the  material  to  roller  
compaction. The soft compacts were milled through 5mm screen with knives 
forward. 
Ø Granules were sifted through 24 mesh, Blend the granules using colloidal 
silicon dioxide and Magnesium stearate of part 2. 
Ø Compression of Lubricated blend using 12.5×7.0 mm punches in 10 station 
rotary compression machine. 
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Table No: 15 Optimization of Rate controlling polymers 
Ingredients Formulation code 
F1(mg) F2(mg) F3(mg) F4(mg) 
Ropinirole HCl 2.28 2.28 2.28 2.28 
HPMC K100M 240 
 
185 - - 
HPMC K15M 60 55 - - 
PVP K90 10 10 10 10 
Castor oil - - 200 184 
Stearic acid - - 56 54 
Anhydrous 
Lactose 
83.22 143.22 127.22 145.22 
Colloidal Sio2 3 3 3 3 
Mg.stearate 1.5 1.5 1.5 1.5 
 
Percentage of drug release 
         The tablets prepared by four formulationsare taken and perform the dissolution 
in USP type 2 apparatus and samples are withdrawn at suitable intervals and 
percentage is calculated in HPLC by calculating peak areas of test sample. 
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Table No: 16 Percentage drug release during optimization of polymers 
Time(h) %  Drug  release (Avg  of   4 Tablets) 
 
F1 
 
F2 F3 F4 
0 0 0 0 0 
1 17±1.0 14±0.3 
 
10±1.0 09±0.3 
 
2 24±0.8 22±0.5 
 
17±1.2 15±0.5 
 
4 39±0.1 33±0.2 
 
21±1.0 
 
22±0.9 
 
8 57±0.0 49±0.9 
 
32±1.1 
 
34±1.0 
 
12 70±0.4 62±0.8 
 
44±1.0 42±1.1 
 
16 79±1.0 72±1.0 49±1.2 
 
50±0.2 
 
20 84±0.9 76±1.2 
 
52±1.0 
 
57±1.0 
 
24 87±0.5 
 
80±1.3 65±1.2 63±1.0 
 
 
 
Figure.6. Time v/s % Drug release (optimization of polymers) 
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Optimization of PVP K90 
         Release of the entrapped drug from a highly viscous and strong matrix is not 
easy. Once the matrix imbibes sufficient water, it increases in path length and blocks 
channeling due to which release tends to stop leading to an incomplete release. A 
release modifier which sufficiently modulates the rigidity of matrix and is necessary 
for obtaining completeness of release 
Procedure 
Ø Rinse API with Anhydrous Lactose part 1 and pass through 30 mesh screen, 
Sift together HPMC K100M and HPMC K15M and pass through 30 mesh 
screen.  
Ø Sift the contents of Anhydrous Lactose part 2 with colloidal silicon dioxide 
and magnesium stearate of part 1 and pass through 30 mesh screen and to 
this PVP K90 is added.  
Ø Blend  the  entire  contents  for  10  minutes  and  subject  the  material  to  roller  
compaction. The soft compacts were milled through 5mm screen with knives 
forward. 
Ø Granules were sifted through 24 mesh, Blend the granules using colloidal 
silicon dioxide and Magnesium stearate of part 2. 
Ø Compression of Lubricated blend using 12.5×7.0 mm punches in 10 station 
rotary compression machine. 
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Table No: 17 Optimization of PVP K90 
Ingredients 
 
Formulation code 
F1(1) (mg) F1(2) (mg) F1(3) (mg) F1(4) (mg) 
Ropinirole 
HCl 
2.28 2.28 2.28 2.28 
HPMC 
K100M 
240 240 
 
240 
 
240 
 
HPMC K15M 60 60 60 60 
PVP K90 50 55 40 60 
Anhydrous 
Lactose 
43.22 38.22 53.22 33.22 
Colloidal Sio2 3 3 3 3 
Mg.stearate 1.5 1.5 1.5 1.5 
 
Percentage of drug release 
        The tablets prepared by four formulations are taken and perform the dissolution 
in USP type 2 apparatus and samples are withdrawn at suitable intervals and 
percentage is calculated in HPLC by calculating peak areas of test sample 
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Table No: 18 Percentage drug release during optimization of PVP K90 
Time(h) %  Drug  release (Avg  of   4 Tablets) 
 
F1(1) F1(2) F1(3) F1(4) 
0 
 
0 0 0 0 
1 16±1.2 
 
18±0.4 14±0.4 20±1.2 
 
2 27±1.0 28±1.2 23±1.0 30±0.1 
 
4 42±1.0 
 
44±1.2 
 
38±0.9 
 
48±0.4 
8 63±1.2 
 
66±1.0 
 
62±1.2 
 
68±0.5 
 
12 74±1.1 
 
78±0.5 
 
70±0.3 80±0.2 
 
16 82±1.2 
 
86±1.2 78±0.9 
 
89±0.9 
 
20 88±0.9 
 
90±0.9 
 
84±0.8 
 
93±0.7 
 
24 92±0.1 
 
96±1.0 90±0.7 98±0.9 
 
 
 
Figure.7. Time v/s % Drug release (Optimization of PVPK 90) 
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Optimization of Sodium carboxy methylcellulose  
        Carboxy methyl cellulose sodium was incorporated to exhibit synergistic effect 
along with Hypromellose in controlling the release throughout the matrix. For 
modulating matrix strength and rigidity, it was necessary to add a fast gelling agent 
like Sodium carboxy methyl cellulose.  
Procedure 
Ø Rinse API with Anhydrous Lactose part 1 and pass through 30 mesh screen, 
Sift together HPMC K100M and HPMC K15M and pass through 30 mesh 
screen.  
Ø Sift the contents of Anhydrous Lactose part 2 with colloidal silicon dioxide 
and magnesium stearate of part 1 and pass through 30 mesh screen and to 
this PVP K90 and Sodium carboxy methyl cellulose is added.  
Ø Blend  the  entire  contents  for  10  minutes  and  subject  the  material  to  roller  
compaction. The soft compacts were milled through 5mm screen with knives 
forward. Granules were sifted through 24 mesh, Blend the granules using 
colloidal silicon dioxide and Magnesium stearate of part 2. 
Ø Compression of Lubricated blend using 12.5×7.0 mm punches in 10 station 
rotary compression machine. 
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Table No: 19 Optimization of Sodium carboxy methyl cellulose 
Ingredients 
 
Formulation code 
F1(4)(1) (mg) F1(4)(2) (mg) F1(4)(3) (mg) 
Ropinirole HCl 2.28 2.28 2.28 
HPMC K100M 240 240 240 
HPMC K15M 60 60 60 
PVP K90 - 35 60 
Sodium carboxy 
methyl cellulose 
75 40 15 
Anhydrous Lactose 18.72 18.72 18.72 
Colloidal Sio2 2 2 2 
Mg.stearate 2 2 2 
 
Percentage of drug release 
        The tablets prepared by four formulations are taken and perform the dissolution 
in USP type 2 apparatus and samples are withdrawn at suitable intervals and 
percentage is calculated in HPLC by calculating peak areas of test sample 
 
 
 
 
 
 
 
 
 
60 
 
Department of Pharmceutics, Avpc  
 
Table No: 20 Percentage drug release during optimization of Sodium carboxy 
methyl cellulose 
Time(h) %  Drug  release (Avg  of   4 Tablets) 
 
F1(4)(1) F1(4)(2) F1(4)(3) 
0 0 0 0 
1 12±0.7 14±0.8 18±0.4 
2 20±0.9 23±1.2 28±0.7 
4 32±1.2 
 
34±1.0 40±1.0 
 
8 50±0.5 53±0.5 62±0.2 
12 63±0.5 
 
67±0.5 74±0.4 
16 73±0.2 
 
77±0.7 82±0.3 
 
20 80±0.9 
 
86±0.4 
 
90±0.5 
 
24 87±1.0 92±1.0 98±0.7 
 
 
Figure.8. Time v/s % Drug release(Optimization of Sodium carboxy methyl 
cellulose) 
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Optimization of functional coating formula 
        Since the drug is moisture sensitive, to protect the drug from atmosphere 
Hydrophobic polymer is used and to have drug release Opadry white is used which 
acts as channel forming agent and thereby drug release is seen. 
Procedure 
Ø Rinse API with Anhydrous Lactose part 1 and pass through 30 mesh screen, 
Sift together HPMC K100M and HPMC K15M and pass through 30 mesh 
screen.  
Ø Sift the contents of Anhydrous Lactose part 2 with colloidal silicon dioxide 
and magnesium stearate of part 1 and pass through 30 mesh screen and to 
this PVP K90 and Sodium carboxy methyl cellulose is added.  
Ø Blend  the  entire  contents  for  10  minutes  and  subject  the  material  to  roller  
compaction. The soft compacts were milled through 5mm screen with knives 
forward. 
Ø Granules were sifted through 24 mesh, Blend the granules using colloidal 
silicon dioxide and Magnesium stearate of part 2. 
Ø Compression of Lubricated blend using 12.5×7.0 mm punches in 10 station 
rotary compression machine. Functional coating is needed since the drug is 
moisture sensitive, to protect the exposure to atmosphere Hydrophobic 
polymer like Ethyl cellulose and Opadry white is used which acts as channel 
forming agent and thereby drug release is seen, and three optimization is 
done 
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Table No: 21 Optimization of Functional Coating 
Ingredients 
 
Formulation code 
F1(4)(3)(1) 
mg 
F1(4)(3)(2) 
mg 
F1(4)(3)(3) 
mg 
Ropinirole HCl 2.28 2.28 2.28 
HPMC K100M 240 240 240 
HPMC K15M 60 60 60 
PVP K90 60 60 60 
Sodium carboxy 
methyl cellulose 
15 15 15 
Anhydrous Lactose 18.72 18.72 18.72 
Colloidal Sio2 2 2 2 
Mg.stearate 2 2 2 
Total 400 400 400 
Ethyl cellulose 10.78 8.62 4.31 
Opadry white 10.78 12.93 17.25 
Tri ethyl citrate 0.44 0.44 0.44 
Isopropyl alcohol q.s q.s q.s 
Dichloromethane q.s q.s q.s 
 
Percentage of drug release 
        The tablets prepared by three formulations are taken and perform the 
dissolution in USP type 2 apparatus and samples are withdrawn at suitable intervals 
and percentage is calculated in HPLC by calculating peak areas of test sample. 
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Table No: 22 Percentage drug release during optimization of Functional 
Coating 
Time(h) %  Drug  release (Avg  of   4 Tablets) 
 
F1(4)(3)(1) F1(4)(3)(2) F1(4)(3)(3) 
0 0 0 0 
1 0 
 
06±0.4 
 
16±0.6 
2 2±0.6 18±1.3 
 
28±0.6 
4 10±0.2 
 
35±0.6 
 
44±0.6 
 
8 32±0.2 
 
57±1.2 65±0.2 
 
12 51±1.0 
 
69±0.5 
 
78±0.6 
16 66±1.0 
 
78±0.3 88±0.6 
 
20 77±1.2 
 
87±1.2 
 
95±0.0 
 
24 85±0.5 
 
92±0.8 98±0.2 
 
 
Figure.9. Time v/s % Drug release(Optimization of functional coating 
formula) 
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Process optimization 
        During process Optimization the finalized formula is taken and tablets are 
prepared by three process, like direct compression, dry granulation and wet 
granulation. The percentage of drug release is almost same in all three process but 
there are issues in wet granulation and direct compression hence finalized the 
process of dry granulation 
Table No: 23 Optimization of process 
Ingredients Direct 
compression 
Dry 
granulation 
Wet 
granulation 
Ropinirole HCl 2.28 2.28 2.28 
HPMC K100M 240 240 240 
HPMC K15M 60 60 60 
PVP K90 60 60 60 
Sodium carboxy 
methyl celluolse 
15 15 15 
Anhydrous 
Lactose 
18.72 18.72 18.72 
Colloidal Sio2 2 2 2 
Mg.stearate 2 2 2 
Purified water - - q.s 
 
Percentage of drug release 
        The tablets prepared by three formulations are taken and perform the 
dissolution in USP type 2 apparatus and samples are withdrawn at suitable intervals 
and percentage is calculated in HPLC by calculating peak areas of test sample. 
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Table No: 24 Percentage drug release during Optimization of Process 
Time(h) %  Drug  release (Avg  of   4 Tablets) 
Direct 
compression 
Dry 
granulation 
Wet 
granulation 
0 0 0 0 
1 13±0.2 15±0.4 14±0.5 
2 22±0.6 25±0.4 20±0.7 
4 36±0.7 59±0.7 35±0.2 
8 58±0.2 65±0.9 56±0.4 
12 74±0.4 78±0.2 72±0.6 
16 82±0.6 84±0.4 80±0.6 
20 89±0.8 91±0.5 86±0.8 
24 94±0.4 96±0.7 92±0.5 
 
 
Figure No.10. Time v/s % Drug release(Optimization of Process) 
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Table No: 25 Final Optimized Formula 
Ingredient 2mg (Qty in mg) 
Ropinirole HCl 2.28 
HPMC K100M 240 
HPMC K15M 60 
PVP K90 60 
Sodium carboxy methyl cellulose 15 
Anhydrous Lactose 18.72 
Colloidal Sio2 2 
Mg.stearate 2 
Total 400 
Functional coating 
Ethyl cellulose 4.31 
Opadry white 17.25 
Tri ethyl citrate 0.44 
Isopropyl alcohol q.s 
Dichloromethane q.s 
% Coating gain 5% 
Film coating 
Opadry pink 14.77 
Purified water q.s 
% Coating  gain 3% 
TOTAL 436.77 
 
Formulation evaluation 
Evaluation of Granules 
Bulk Density (Db) 47 
        It  is  the  ratio  of  total  mass  of  powder  to  the  bulk  volume  of  powder.  It  was  
measured by Pouring the weight powder (passed through standard sieve # 20) into a 
measuring cylinder and initial weight was noted. This initial volume is called the 
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bulk  volume.  From  this  the  bulk  density  is  calculated  according  to  the  formula  
mentioned below. It is expressed in g/ml and is given by 
ܦܾ = ܯ
ܸܾ
 
Where, M is the mass of powder, 
Vb  is the bulk volume of the powder. 
Tapped Density (Dt) 
        It is the ratio of total mass of the powder to the tapped volume of the powder. 
Volume was measured by tapping the powder for 750 times and the tapped 
volume was noted if the difference between these two volumes is less than 2% 48. 
If it is more than 2%, tapping is continued for 1250 times and tapped volume was 
noted. Tapping was continued until the difference between successive volumes is 
less than 2 % (in a bulk density apparatus). It is expressed in g/ml and is given by 
ܦݐ = ܯ
ܸݐ
 
Where,  M is the mass of powder, 
Vt is the tapped volume of the powder. 
Angle of Repose (Ө) 49 
        The friction forces in a loose powder can be measured by the angle of repose 
(Ө).  It  is  an  Indicative  of  the  flow  properties  of  the  powder.  It  is  defined  as  
maximum angle possible between the surface of the pile of powder and the 
horizontal plane 
Tan(ߠ) =  
ݎ
 
Ө= tan-1 (h / r) 
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Where,Ө is the angle of repose.h is the height in cms, r is the radius in cms. 
        The powder mixture was allowed to flow through the funnel fixed to a stand at 
definite height (h). The angle of repose was then calculated by measuring the height 
and radius of the heap of powder formed.  
Table No: 26 Angle of Repose as an Indication of Powder Flow Properties 
Angle of repose Flow ability 
<25 Excellent 
26-30 Good 
31-35 Passable 
>35 Very Poor 
 
Carr’s index (or) % compressibility 
        It indicates powder flow properties. It is expressed in percentage and is give 
  ܥ݋݉݌ݎ݁ݏݏܾ݈݅݅݅ݐݕ	ܫ݊݀݁ݔ = 	 ఘ೟ೌ೛೛೐೏షఘ್ೠ೗ೖ
ఘ೟ೌ೛೛೐೏
  x 100 
Where, Dt is the tapped density of the powder and 
           Db is the bulk density of the powder. 
Table No: 27 Relationship between % compressibility and flow ability 
% Compressibility Flow ability 
5-12 Excellent 
12-16 Good 
18-21 Fair Passable 
23-35 Poor 
33-38 Very Poor 
<40 Very very Poor 
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Hausner ratio 
        Hausner ratio is an indirect index of ease of powder flow. It is calculated by the 
following Formula.  
  ܪܽݑݏ݊݁ݎ		ܴܽݐ݅݋	 = 	 ்௔௣௣௘ௗ	ௗ௘௡௦௜௧௬
஻௨௟௞	ௗ௘௡௦௜௧௬
  
Where, Dt is the tapped density. 
           Db is the bulk density. 
Lower hausner ratio (<1.25) indicates better flow properties than higher ones 
(>1.25). 
Table No: 28 Derived and flow properties of Granules of formulation 
 
 
Formulation 
Code 
Bulk 
Density ±  
SD 
Tapped 
density ±  
SD 
    Angle of   
Repose ± 
SD 
Carr’s 
Index ±  
SD 
Hausner’s 
ratio ±  
SD 
F1 0.421±0.03 0.482± 0.2 25.20 ± 0.7 12.6 ± 2.2 1.14 ± 0.2 
F2 0.469 ± 1.2 0.544 ± 1.1 25.12 ± 1.2 13.8 ± 1.1 1.16 ± 1.3 
F3 0.469 ± 1.8 0.550 ± 1.7 26.56 ± 1.9 14.7 ± 1.9 1.17 ±1.1 
F4 0.434 ± 1.5 0.508 ± 1.6 25.20 ± 1.8 14.5 ± 1.8 1.17 ± 1.7 
F1(1) 0.459 ± 1.3 0.534 ± 1.3 24.77 ± 1.3 14.0 ± 1.4 1.16 ± 1.2 
F1(2) 0.493 ± 0.9 0.570 ± 1.0 26.34 ± 1.4 13.5 ± 1.1 1.16 ± 1.2 
F1(3) 0.471±0.02 0.542± 0.2 27.60 ± 0.4 13.1± 2.1 1.15 ± 0.3 
F1(4) 0.521 ± 0.8 0.601 ± 0.9 24.32 ± 1.5 13.3 ± 0.8 1.15 ± 0.6 
F1(4)(1) 0.458 ± 0.4 0.522 ± 0.5 22.78 ±1.2 12.2 ± 0.3 1.14 ± 0.2 
F1(4)(2) 0.462 ± 0.5 0.528 ± 0.6 23.12 ± 1.4 12.5 ± 0.7 1.14 ± 0.8 
F1(4)(3) 0.516 ± 0.7 0.582 ± 0.8 23.56 ± 1.6 11.3 ± 0.6 1.12 ± 0.5 
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Physico-chemical evaluation of tablets 
Thickness and hardness 
        The Thickness and Hardness of the each tablet was measured by using Varian 
automatic Thickness and Hardness tester and the average Thickness and Hardness in 
mm and kp was calculated. 
 
Friability50 
        The Roche friability test apparatus was used to determine the friability of the 
tablets. Twenty pre-weighed tablets were placed in the apparatus and operated for 
100 revolutions and then the tablets were reweighed. The percentage friability was 
calculated according to the following formula. 
 
% Friability =   Initial Weight-  Final Weight     X 100 
     Initial Weight 
Weight variation51 
        Formulated tablets were tested for weight uniformity, 20 tablets were weighed 
collectively and individually. From the collective weight, average weight was 
calculated. The percent weight variation was calculated by using the following 
formula. 
100
 WeightAverage
 WeightIndividual - Weight Average
 Variation  Weight % X=  
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Table No: 29 Avg wt of Tablet and %Deviation 
Avg.wt of Tablet % Deviation 
130mg or less ±10 
More than 130mg but less than 
324mg 
±7.5 
More than 324mg ±5 
 
Assay (Drug content) 52 
Mobile phase: Buffer: Acetonitrile (80:20) 
Diluents:      Dil-1 (Acetonitrile: Methanol-80:20) 
                Dil-2 (milliQ water) 
Standard stock preparation 
 Transfer accurately weighed amount of 55mg reference standard to 200 ml 
volumetric flask add 80ml of diluents-2,sonicate to dissolve the material and dilute 
the volume with diluents-2 and mix well. 
Standard preparation 
 Pipette 5ml of std.stock solution to 100ml volumetric flask and dilute the 
volume with diluent-2. 
Test preparation 
 Transfer 10 tablets into 500ml volumetric flask, add about 200ml methanol 
and150ml dil-1sonicate for 40 min with intermediate shaking. Centrifuge the above 
solution for 10 min. pipette out 5ml of clear supernatant into 25ml volumetric flask 
and made upto mark with diluent-2. 
Equipment                               -Waters type with UV detector 
Column Temperature              -300c 
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Flow Rate                                -1.2ml/min 
Injection volume                      -80µL 
Qty of Ropinirole present in portion of tablet is 
ܣ௧
ܣ௦
× ௦ܹ200 × 5100 × 500ܲ × 255 × ܰ100 × 100ܮ  
              At -Peak Area of test preparation in nth time 
              As –Peak Area of standard preparation 
             ws- Weight of Ropinirole HCl working standard taken in mg 
              P -Potency of Ropinirole working standard 
              N –No. of tablets taken 
              L -Labelled amt of Ropinirole (2mg)  
Table No: 30 Evaluation of Tablets of Formulation 
Formulation 
Code 
Hardness 
(kp) 
Thickness 
(mm) 
 
Friability 
 
% Weight 
variation 
 
Assay (%) 
F1 08 ± 0.7 5.4 ± 0.6 0.30 ± 0.8 1.2 ± 0.6 92 ± 0.5 
F2 10 ± 0.2 5.3 ± 1.7 0.36 ± 0.5 2.4 ± 0.4 90 ± 0.6 
F3 14 ± 0.6 5.5 ± 1.5 0.40 ± 0.4 2.8 ± 0.3 86 ± 0.5 
F4 16 ± 0.7 5.4 ± 0.3 0.25 ± 0.2 3.2 ± 0.4 88 ± 1.3 
F1(1) 10 ± 0.3 5.5 ± 0.2 0.35 ± 0.5 2.8 ± 0.2 92 ± 1.2 
F1(2) 12 ± 0.2 5.6 ± 0.4 0.55 ± 0.6 2.6 ± 0.3 94 ± 0.7 
F1(3) 10 ± 1.4 5.8 ± 0.1 0.45 ± 0.2 2.2 ± 0.4 96 ± 1.2 
F1(4) 12 ± 0.8 5.7 ± 0.2 0.40 ± 0.3 2.4 ± 0.4 94 ± 0.2 
F1(4)(1) 14 ± 1.0 5.9 ± 0.3 0.30 ± 0.4 1.9 ± 0.6 96 ± 0.5 
F1(4)(2) 13 ± 0.8 5.6 ± 0.4 0.28 ± 0.6 1.8 ± 0.2 95 ± 0.3 
F1(4)(3) 10 ± 0.5 5.5 ± 0.8 0.20 ± 0.4 1.6 ± 0.5 99 ± 0.2 
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IN-VITRO DRUG RELEASE STUDY53 
        The USP type IIrotating paddle method was used to study the drug release from 
the tablets. The dissolution medium consisted of 500 ml of Citrate buffer pH 4. The 
release study was performed at 37 ± 0.50 C, with a rotation speed of 100 rpm. 
Aliquots (5ml each) were withdrawn at regular time intervals and replaced with 
fresh medium to maintain sink conditions. The samples were filtered, and were 
analyzed in H.P.L.C. 
        The kinetic models used were a zero-order equation, higuchi’s model and 
peppa’s models. The obtained results in these formulations were plotted in various 
model treatment are as follows. i.e. Cumulative percentage release of drug Vs 
Square root of time (Higuchi’s)54and Log cumulative percentage release Vs Log 
time (Peppas)55. To know the mechanism of drug release of Ropinirole from the 
tablet the drug release data was fit into higuchi’s models.  
Table No: 31  In-vitro Drug release and Higuchi data for formulations F1- F1 
(4) 
Time 
(h) 
Sqrt 
of 
time 
% Cumulative drug release 
F1 F2 F3 F4 F1(1) F1(2) F1(3) F1(4) 
 
0 0 0 0 0 0 0 0 0 0 
1 1.000 17 14 10 09 16 18 14 20 
2 1.414 24 22 17 15 27 28 23 30 
4 2.000 39 33 21 22 42 44 38 48 
8 2.828 57 49 32 34 63 66 62 68 
12 3.464 70 62 44 42 74 78 70 80 
16 4.000 79 72 49 50 82 86 78 89 
20 4.472 84 76 52 57 88 90 84 93 
24 4.898 87 80 65 63 92 96 90 98 
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Table No: 32Peppa’s data for Formulation F1-F1 (4) 
 
Time (h) Log time Log % Cumulative drug release 
F1 F2 F3 F4 F1(1) F1(2) F1(3) F1(4) 
 
1 0 1.23 1.15 1.00 0.95 1.20 1.25 1.14 1.30 
2 0.301 1.38 1.34 1.23 1.18 1.43 1.45 1.36 1.48 
4 0.602 1.59 1.52 1.32 1.34 1.62 1.64 1.58 1.68 
8 0.903 1.76 1.69 1.50 1.53 1.81 1.81 1.79 1.83 
12 1.079 1.85 1.79 1.64 1.62 1.87 1.89 1.85 1.92 
16 1.204 1.90 1.86 1.69 1.70 1.91 1.93 1.89 1.95 
20 1.301 1.92 1.88 1.72 1.76 1.94 1.95 1.92 1.97 
24 1.380 1.94 1.92 1.81 1.80 1.96 1.98 1.95 1.99 
 
 
Figure No.11. In-vitro drug release data for formulation F1-F1 (4) 
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Figure No.12.Higuchi plot of formulation F1-F1 (4) 
 
 
Figure No.13.Peppa’s plot of formulation F1-F1 (4) 
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Table No: 33 In-vitro Drug release and Higuchi data for formulations F1(4)(1)- 
F1(4)(3(3) 
Tim
e  
(h) 
Sqrt 
of 
time 
% Cumulative drug release 
F1(4)(1
) 
F1(4)(2
) 
F1(4)(3
) 
F1(4)(3)(1
) 
F1(4)(3)(2
) 
F1(4)(3)(3
) 
0 0 0 0 0 0 0 0 
1 1.00
0 12 14 18 0 06 16 
2 1.41
4 20 23 28 2 18 28 
4 2.00
0 32 34 40 10 35 44 
8 2.82
8 50 53 62 32 57 65 
12 3.46
4 63 67 74 51 69 78 
16 4.00
0 73 77 82 66 78 88 
20 4.47
2 80 86 90 77 87 95 
24 4.89
8 87 92 98 85 92 98 
 
Table No: 34 Peppa’s data for Formulation F1(4)(1)- F1(4)(3(3) 
Tim
e  
(h) 
Log 
time 
Log % Cumulative drug release 
F1(4)(1
) 
F1(4)(2
) 
F1(4)(3
) 
F1(4)(3)(1
) 
F1(4)(3)(2
) 
F1(4)(3)(3
) 
1                  0 1.07 1.15 1.25 0.84 0.78 1.21 
2 0.30
1 1.30 1.36 1.45 1.23 1.26 1.45 
4 0.60
2 1.51 1.53 1.62 1.42 1.54 1.64 
8 0.90
3 1.72 1.72 1.79 1.61 1.76 1.81 
12 1.07
9 1.80 1.82 1.87 1.72 1.84 1.89 
16 1.20
4 1.86 1.89 1.91     1.82 1.89 1.94 
20 1.30
1 1.91 1.93 1.95 1.89 1.94 1.98 
24 1.38
0 1.94 1.93 1.99 1.93 1.96 1.99 
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Figure No.14.In-vitro drug release data for formulation F1(4)(1)-F1(4)(3)(3) 
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Figure No.15. Higuchi plot of formulation F1(4)(1)-F1(4)(3)(3) 
 
Figure No.16. Peppa’s plot of formulation F1(4)(1)-F1(4)(3)(3) 
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 IN-VITRO DRUG RELEASE STUDY WHEN COMPARED WITH 
INNOVATOR PRODUCT 
        The Tablet from the finalized or optimized formula is taken and it is compared 
with Innovator medium (pH 4 Citrate buffer) is used and compare the dissolution 
profiles of our formulation and innovator formulation56 
Table No: 35 Requirements in Dissolution 
Medium pH 4 Citrate buffer 
Quantity 500ml 
Apparatus USP Type 2(paddle) 
RPM 100 rpm 
Temperature 37±0.50c 
 
 
Table No: 36 Significance of Similarity factor 
S.no Similarity factor (f2) Significance 
1 < 50 Test and Reference are 
dissimilar 
2 50-100 Test and Reference are Similar 
3 100 Test and Reference are Identical 
4 >100 Equation yield negative value 
 
Percentage of drug release 
        The tablets prepared by Finalized formulation are taken and perform the 
dissolution in USP type 2 apparatus and samples are withdrawn at suitable intervals 
and percentage is calculated in HPLC by calculating peak areas of test sample 
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Table No: 37 Percentage drug release of Finalized and Innovator 
Formulation 
Time(h) %  Drug  release (Avg  of   10 Tablets) 
 
Finalized formulation Innovator formulation 
0 0 0 
1 11±0.1 14±0.4 
2 18±0.2 22±0.3 
4 29±0.2 36±0.2 
8 48±0.3 55±0.5 
12 65±0.4 70±0.2 
16 79±0.3 82±0.7 
20 89±0.2 90±0.6 
24 95±0.5 96±0.2 
 
 
Figure.17.Comparitive dissolution profile in pH 4 Citrate buffer 
Comparitive dissolution profile in pH 6.8 Phosphate buffer 
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        The Tablet from the finalized or optimized formula is taken and it is compared 
with  Innovator  medium  (pH  6.8  Phosphate  buffer)  is  used  and  compare  the  
dissolution profiles of our formulation and innovator formulation 
 
 
Table No: 38 Requirements in Dissolution Medium of pH 6.8 Phosphate buffer 
Medium pH 6.8 Phosphate buffer 
Quantity 500ml 
Apparatus USP Type 2(paddle) 
RPM 100 rpm 
Temperature 37±0.50c 
 
Percentage of drug release 
        The tablets prepared by the Finalized formulation are taken and perform the 
dissolution in USP type 2 apparatus and samples are withdrawn at suitable intervals 
and percentage is calculated in HPLC by calculating peak areas of test sample. 
Table No: 39 Percentage drug release of Finalized v/s Innovator Formulation in 
pH 6.8 Phosphate buffer 
Time(h) %  Drug  release (Avg  of   10 Tablets) 
Finalized formulation Innovator formulation 
0 0 0 
1 12±0.2 08±0.5 
2 21±0.1 14±0.2 
4 35±0.3 28±0.5 
8 54±0.4 46±0.4 
12 66±0.5 62±0.1 
16 75±0.3 74±0.4 
20 82±0.2 85±0.3 
24 89±0.3 96±0.1 
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Figure.18. Comparitive dissolution profilein pH 6.8 Phosphate buffer 
Comparitive dissolution profile in pH 1.2 HCl 
        The Tablet from the finalized or optimized formula is taken and it is compared 
with Innovator medium (pH 1.2 HCl) is used and compare the dissolution profiles of 
our formulation and innovator formulation 
Table No: 40 Requirements in Dissolution Medium of pH 1.2 HCl 
Medium pH 1.2 HCl 
Quantity 500ml 
Apparatus USP Type 2(paddle) 
RPM 100 rpm 
Temperature 37±0.50c 
 
Percentage of drug release 
        The tablets prepared by the Finalized formulation are taken and perform the 
dissolution in USP type 2 apparatus and samples are withdrawn at suitable intervals 
and percentage is calculated in HPLC by calculating peak areas of test sample. 
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Table No: 41 Percentage drug release of Finalized v/s Innovator Formulation in 
pH 1.2 HCl 
Time(h) %  Drug  release (Avg  of   10 Tablets) 
Finalized formulation Innovator formulation 
0 0 0 
1 16±0.1 12±0.0 
2 25±0.3 21±0.2 
4 39±0.4 32±0.3 
8 60±0.6 54±0.4 
12 72±0.4 69±0.7 
16 84±0.2 83±0.5 
20 89±0.2 90±0.3 
24 92±0.3 96±0.2 
 
 
Figure.19.Comparitive dissolution profile inpH1.2 HCl 
STABILITY DETAILS57-59 
        Accelerated stability study carried out as per ICH Guidelines “Q1E, Evaluation 
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formulation  was  selected  and  stability  study  was  carried  out  at  different  condition  
such as refrigerator, long term and accelerated conditions for 3 months. 
        About 15 tablets packed in HDPE bottles and kept at above specified condition 
in stability chamber for three months. Tablet samples evaluated after 1st,2nd and 3rd 
month for drug content58 as well as subjected for in vitro drug release study. all the 
parameters have not shown any much variation when compared to initial data. The 
dissolution59 release profiles were analyzed with aid of dissolution similarity factor 
f2 and time point analysis. 
 
Table No: 42 Stability data 
 
 
 
Stage Specification
s 
 
Initial 
 
40oc/75%R
H 
-1M 
40oc/75%R
H 
-2M 
40oc/75%R
H 
-3M 
Assay 
(%) 
90 to 110% 98±0.1 96.3±0.2 96.1±0.3 93.9±0.2 
Despropy
l 
0.5% 0.14±0.0
2    0.21±0.04     0.28±0.03 0.29±0.05 
3-oxo 0.5% 0.05±0.0
3 
0.07±0.04 0.09±0.02 0.11±0.01 
N-Methyl 0.5% 0.12±0.0
1 
0.32±0.03 0.35±0.01 0.38±0.02 
N-oxide 0.5% 0.09±0.0
3 
0.11±0.04 0.14±0.02 0.16±0.01 
1hr (%) 5 to 20% 14±0.8 13±0.4 12±0.6 10±0.5 
8 hr(%) 45 to 70% 55±1.2 53±0.8 52±1.0 50±0.9 
24 hr(%) NLT 80% 96±1.4 89±1.2 86±1.6 84±1.3 
Physical observation white No 
change in 
colour 
No 
change in 
colour 
No 
change in 
colour 
  
 
 
 
 
 
 
 
 
 
 
Results And Discussion 
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RESULTS AND DISCUSSION 
Preformulation studies                                                                                                 
        The  Preformulation studies done initially for pure API, confirmed that  active 
ingredient is high soluble,90% of particle is less than 50 microns measured by 
Malvern sizer, flow property is less, hence need of lubricant and magnesium 
stearate.The results were shown in Table No:9. 
Drug-Excipient Compatibility 
        Drug and Excipients were passed through 40mesh screen and mixed in suitable 
ratios and loaded in glass vials and analysed the impurity levels for Initial week and 
Fourth week in HPLC.  
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Table No: 43 Observation of Drug-Excipient compatibility 
COMBINATION ISSUES OVERCOME 
Drug + PVPK-90 Leads to increase in N-
Oxide impurity when it is 
intimate contact with API. 
PVP in our formulation is 
added at a stage where API 
is sufficiently diluted with 
HPMC and Lactose, hence 
intimate contact is 
avoided. 
Drug +Colloidal Sio2 
 
Drug + Mg. Stearate 
Leads to increase in 3-
OXO impurity when it is 
intimate contact with API. 
 
Colloidal sio2 and 
Mg.stearate are added both 
during pre and post 
compaction stages, where 
the  ingredients  are  not  in  
intimate contact with API. 
Drug +Opadry pink 
 
Drug+ Ethyl cellulose 
 
Drug + Tri ethyl citrate 
Also found to increase 
upon intimate contact 
with API 
These ingredients are 
coating agents where they 
are not in intimate contact 
with API, hence 
replacement was not found 
to be necessary. 
Drug + Stearic acid 
 
Drug + Citric acid 
 
Drug + PEG 6000 
 
Leads to much increase in 
impurity levels 
 
These are not used because 
of  Incompatibility, hence 
they are ignored 
 
 
Product development 
Selection of process 
        Since the drug is moisture and heat sensitive, we cannot proceed with wet 
granulation in addition to that tablets in wet granulation leads to increase in 
Despropyl and N-methyl Hydroxyl impurity. In Direct compression leads to increase 
in content and blend un uniformity, hence it is also ignored. With dry granulation 
Absence of impurity level and there will not content and blend un uniformity, in 
addition to that flow property is increased hence we selected dry granulation process 
in optimisation. 
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Formulation development  
Optimization of rate controlling polymers 
        During this stage, optimization of polymers using Hydrophilic and 
Hydrophobic polymers was done.F1 and F2 shows good release over F3 and F4 
because  F3  and  F4  are  use  of  hydrophobic  polymers,  hence  confirmed  the  use  of  
Hydrophilic polymers (F1) in our Formulation. 
Optimization of PVP K90 
        Release of Entrapped drug from highly viscous matrix is not easy, leading to 
incomplete release, hence a release modifier which modulates the rigidity of matrix 
is necessary for obtaining completeness of release. Among the four formulations F1 
(4) gives best results and hence used in formulation. 
Optimization of Sodium carboxy methylcellulose  
        Complete Replacement of PVPK 90 with Sodium carboxy methyl cellulose 
caused the dissolution profile to be slower and completeness of drug release is not 
achieved, hence it was decided to partially replace PVPK 90 rather than complete 
replacement. 
Optimization of functional coating formula 
        Among all ratios of Ethyl cellulose and Opadry white (50:50, 40:60, 20:80) the 
ratio of 20:80 was found to provide the desired release profile because Ethyl 
cellulose is Hydrophobic it will retard the drug release with increase in 
concentration. 
Process optimization 
        The results came to know that the percentage of drug release is almost same in 
all  process.  But  there  are  no  issues  in  dry  granulation;  in  addition  to  that  flow  
property is increased and hence finalized use of Dry granulation. 
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Formulation Evaluation 
Evaluation of granules 
        The granules are evaluated for Bulk density, tapped density, Angle of repose 
Carr’s index, Hausner ratio by following the procedures as per pharmacopoeia.The 
results were satisfactory and were shown in Table No: 28. 
Thickness, Weight variation, Hardness and Friability 
        The prepared tablets were characterized for thickness, weight variation, 
hardness and friability by following the procedures as per pharmacopoeia, to check 
the stability of tablets during transportation, packaging and storage. The results 
obtained in all the formulations were within pharmacopoeia standards. The results 
were tabulated in Table No: 30. 
In-vitro Release kinetics 
        Data of in-vitro release were fit into different equations and kinetic models to 
explain the release kinetics of Ropinirole from the tablet. To find out the mechanism 
of drug release from hydrophilic matrices, the in-vitro dissolution  data  of  each  
formulation with different kinetic drug release equations. Namely Zero order: 
Q=K0t; Higuchi’s square rate at time: Q=KHt1/2 and Peppas: F=Kmtn 60, where Q is 
amount  of  drug  release  at  time t,  F  is  Fraction  of  drug  release  at  time t,  K0 iszero 
order kinetic drug release constant, KHis Higuchi’s square root of time kinetic drug 
release constant, Km is constant incorporatinggeometric and structural characteristic 
of the films and n is the diffusion exponent indicative of the release mechanism.  
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Table No: 44 Diffusion characteristics of Ropinirole Extended release tablet 
formulations 
Formulation code Correlation coefficient values (R2) Diffusion 
exponent value 
(n) 
Zero Order Higuchi’s Model 
F1 0.945 0.995 0.535 
F2 0.955 0.996 0.555 
F3 0.975 0.993 0.560 
F4 0.978 0.997 0.604 
F1(1) 0.939 0.993 0.547 
F1(2) 0.936 0.992 0.530 
F1(3) 0.944 0.992 0.588 
F1(4) 0.931 0.991 0.505 
F1(4)(1) 0.969 0.997 0.628 
F1(4)(2) 0.969 0.998 0.590 
F1(4)(3) 0.955 0.997 0.531 
F1(4)(3)(1) 0.991 0.965 0.742 
F1(4)(3)(2) 0.959 0.990 0.805 
F1(4)(3)(3) 0.944 0.994 0.567 
 
 
Table No: 45 Diffusion exponent drug release mechanism60 
S. No. Diffusion exponent value (n) Drug release mechanism 
1 < 0.45 Fickian release 
2 0.45 to 0.89 Non fickian release 
3 0.89 Case II transport 
4 > 0.89 Super case II transport 
 
In-vitro drug release study when compared with Innovator Product 
        The Tablet from the finalized or optimized formula is taken and it is compared 
with Innovator medium (pH 4 Citrate buffer) is used and compare the dissolution 
profiles of our formulation and innovator formulation. The percentage of drug 
release is almost same to the innovator formulation, in addition to that when 
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compared with other dissolution medium like pH 1.2 HCl and pH 6.8 Phosphate 
buffer, dissolution profiles conclude that test and reference products are 
pharmaceutically equivalent. 
Release kinetics when compared with Reference formulation 
 
Fig.20. Higuchi plot of Finalized v/s Reference formulation 
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           Fig.21. Zero order kinetics of Finalized v/s Reference formulation 
 
 
 
Fig.22. Peppa’s plot of Finalized v/s Reference formulation 
Table No: 46 Comparitive Diffusion characteristics of Finalized v/s Reference 
Formulation Correlation coefficient 
values (R2) 
Diffusion exponent 
value (n) 
Zero 
Order 
Higuchi’s 
Model 
Optimized formulation 0.969 0.992 0.610 
Reference formulation 0.982 0.993 0.695 
Concludes our Finalized and Reference formulation follows Higuchi model Non-
fickian transport  
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Stability studies 
The stability studies of Finalised formulation were carried out at accelerated 
condition of 40±2 0C, 75±5 % RH conditions for 3 months periodically checked at 
1Month, 2 Month, and 3 Month for Impurities, Assay, and Dissolution. The results 
are within specification61 are tabulated in Table No: 42. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Summary And Conclusion 
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SUMMARY AND CONCLUSION 
         Ropinirole Extended Release Tablets were Generic product of REQUIP 
XL(Innovator) of GlaxoSmithKline. The Preformulation studies includes drug 
excipient compatibility by HPLC was conducted and the results obtained showed 
that good compatible with Ropinirole.In the present study, the tablets were prepared 
by dry granulation. During the core optimization, formulation (F1(4)(3)(3)) shows 
better drug release over 24 hrs of time and its release is 98%, this formula is 
optimized for functional coating optimization, Among ratios of ethyl cellulose and 
Opadry white the ratio of 20:80 was found to provide the desired release profile and 
the tablets were evaluated for Thickness, Hardness, Friability, and Assay. From the 
drug release kinetics follows Higuchi model Non-fickian transport. Dissolution 
profile concludes that our product and innovator product are pharmaceutically 
equivalent. Stability studies conducted according to ICH guidelines carried out for a 
period of 3 months in short term period. The results were within the specification at 
accelerated conditions concludes our formulation is stable. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Bibilography 
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